SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

HLS Sees 2026 Adjusted EBITDA in Lower Half of Guidance

HLS Therapeutics expects 2026 adjusted EBITDA in the lower half of its $18.5 million-$21 million guidance range.

HLS

Related stories